Apricus Biosciences, Inc. is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has initiated a Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions.

Apricus Biosciences

Pharmaceutical

United States of America

The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The pharmaceutical industry is developing at an unusually rapid pace. The market for pharmaceuticals is growing persistently, and expenses for drugs will amount to $1.5 trillion globally by 2021. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. Investments in biopharmaceutical innovation are driving contributions to the American economy and solidifying America’s role as a leader in medical innovation. The pharmaceuticals sector is forecasted to grow faster than any other market in the next five years with an emphasis on R&D.

Careers and Openings at Apricus Biosciences